Andrea Wagner, MSN, RN, OCN, of the Hackensack University Medical Center, speaks about enhancing autonomy through a nurse-driven tocilizumab order for treatment of cytokine release syndrome (CRS) during the 49th Annual Oncology Nursing Society (ONS) Congress.
“This is an important topic, especially with today’s treatment landscape. Treatment in oncology is really moving toward immunotherapy,” she said, noting that chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies are notable recent developments that can have advantages over traditional oncology treatments, but can come with short-term effects such as CRS.
